★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,255 Indexed Studies

Major Medical Journal Watch (NEJM, Lancet, JAMA, BMJ, Nature Med) (120 Indexed Studies)

Q: Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

Q: How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Q: Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

Q: How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.

Recent publications, longitudinal cohorts, and clinical practice updates from The New England Journal of Medicine, The Lancet, JAMA, BMJ, and Nature Medicine. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Read the Full Breakthrough Breakdown → Jump to All 15 Landmark Breakthroughs ↓

Inside the Clinical Evidence Lab: Our research desk audits 6,255 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.

1. Major Clinical Breakthroughs & Deep-Dive Study Breakdowns (16 Guides)

Landmark Clinical Breakthroughs & Head-to-Head Trial Reviews

Plain-English breakdowns of the most important human trials—showing actual benefit percentages (ARR/NNT), dosing rules, and who should be careful.

Double-Blind Placebo-Controlled Sleep & Glycine RCTs N = 620 Adults Across 3 Human Trials

Why Magnesium Glycinate Calms Racing 2:00 A.M. Thoughts Without Leaving You Groggy the Next Morning

Bottom-Line Trial Result: Sleep Onset Latency: -17.4 Minutes (p = 0.002) • Serum Cortisol: -18% vs. Placebo • Serum Melatonin: +34% (p < 0.01)

A clinical evidence breakdown of how elemental magnesium blocks excitatory NMDA glutamate receptors while its glycine amino acid carrier lowers core body temperature via the suprachiasmatic nucleus—plus real RCT numbers on sleep latency, cortisol, and supplement label math.

Supplement: Magnesium Glycinate Condition: Insomnia

8 Min Read • 1,380 Words Read Study Guide →

Isotope Fractional Absorption & Metabolic Balance RCTs N = 480 Subjects Across 4 Human PK Trials

Magnesium Glycinate vs. Citrate vs. Oxide: What Human Bioavailability Trials Show About Absorption and Stomach Upset

Bottom-Line Trial Result: Fractional Absorption: Magnesium Oxide ~4% vs. Chelated Bisglycinate ~23.5% (+488% Relative Bioavailability, p < 0.001)

Why inorganic Magnesium Oxide absorbs at just 4% in human fractional absorption studies—and how amino-acid chelation allows Magnesium Bisglycinate to cross the intestinal wall via PEPT1 dipeptide channels without drawing water into the colon.

Supplement: Magnesium Glycinate Condition: GERD & Gut Motility

8 Min Read • 1,260 Words Read Study Guide →

Randomized Double-Blind Precision Nutrition Trial N = 1,180 Participants Across 4 Studies

Why Vitamin D3 Barely Works When You Are Low in Magnesium—Plus What Clinical Trials Show for Nighttime Leg Cramps

Bottom-Line Trial Result: CYP2R1 / CYP27B1 Activation: Sufficient Mg lowers risk of Vitamin D insufficiency (<30 ng/mL) by 46% (p < 0.001)

Every hepatic and renal enzyme that converts cholecalciferol (Vitamin D3) into active 1,25-dihydroxyvitamin D requires magnesium as an obligatory cofactor—explaining "Vitamin D resistance" and nocturnal calf muscle hyperexcitability.

Supplement: Vitamin D3 Supplement: Magnesium Glycinate

8 Min Read • 1,290 Words Read Study Guide →

Pharmacokinetic & GI Tolerability Crossover Trials N = 1,680 Patients Across 4 Trials

Why Metformin (Glucophage & Glycomet) Upsets Your Stomach—and the Extended-Release (ER) Switch That Cuts GI Side Effects in Half

Bottom-Line Trial Result: GI Adverse Events: 26.3% -> 11.7% After IR-to-ER Switch (ARR: 14.6%, RRR: 55%, p < 0.001) • Diarrhea 18.4% -> 6.9%

A clinical synthesis of human pharmacokinetic crossover trials (Timmins et al., PMID: 16176111), GI tolerability cohorts (Blonde et al., PMID: 15140331), and dose-response studies (Garber et al., PMID: 9428832) explaining why unabsorbed gut Metformin triggers diarrhea and how GelShield ER matrices resolve it.

Rx: Metformin ER Condition: Type 2 Diabetes

7 Min Read • ~1,150 Words Read Study Guide →

DPPOS 13-Year Longitudinal Cohort & HOME RCT N = 2,155 Patients (4.3–13 Years)

Metformin (Glucophage & Glycomet) and Vitamin B12 Deficiency: Why Fatigue and Tingling Feet Get Missed

Bottom-Line Trial Result: Total Serum B12: -19% vs. Placebo (p < 0.001) • Biochemical Deficiency (<203 pg/mL): 13% increased risk per year of exposure

A clinical synthesis of the 13-year Diabetes Prevention Program Outcomes Study (Aroda et al., PMID: 26900641), the 4.3-year BMJ randomized controlled trial (de Jager et al., PMID: 20488910), and ileal calcium-channel absorption studies (Bauman et al., PMID: 10977046) explaining how Metformin depletes Vitamin B12 and how to fix it.

Rx: Metformin ER Supplement: Vitamin B12

7 Min Read • ~1,150 Words Read Study Guide →

UKPDS 34 (10.7-Yr RCT) & Bannister Cohort N = 180,000+ Cohort + 1,704 RCT Patients

Metformin (Glucophage & Glycomet) Longevity & Heart Research: What UKPDS, TAME, and Exercise Trials Actually Show

Bottom-Line Trial Result: All-Cause Mortality: RRR 36% (p = 0.011) • Myocardial Infarction: RRR 39% (p = 0.010) • DPP-4 VO2max Attenuation Caveat

A clinical synthesis of the 10.7-year UKPDS 34 cardiovascular mortality trial (PMID: 9742977), the TAME geroprotective protocol (Barzilai et al., PMID: 27304507), and the older-adult exercise blunting trial (Konopka et al., PMID: 30548390)—separating proven diabetic survival gains from healthy-person anti-aging hype.

Rx: Metformin ER Condition: Type 2 Diabetes

8 Min Read • ~1,200 Words Read Study Guide →

24-Hour Continuous Glucose Monitoring (CGM) Study N = 248 Non-Insulin T2D Patients

Why Is My Blood Sugar High in the Morning—Even When I Didn’t Eat Breakfast? (The Dawn Phenomenon Explained)

Bottom-Line Trial Result: Morning Glucose Surge: +20 to +45 mg/dL Between 3:00 AM and 8:00 AM • Adds +0.4% to Overall HbA1c (p < 0.001)

Waking up to a 145 or 165 mg/dL fasting reading after an early, healthy dinner feels deeply frustrating. Continuous glucose monitoring (CGM) studies show that in 55% of Type 2 diabetes patients, a 3:00 A.M. to 8:00 A.M. surge of growth hormone and cortisol triggers the liver to dump stored sugar (+20 mg/dL fasting glucose and +0.4% HbA1c). Here is how to tell the Dawn Phenomenon apart from the Somogyi rebound—and 4 evening adjustments that calm it down.

Condition: Type 2 Diabetes Rx: Metformin ER

7 Min Read • ~1,250 Words Read Study Guide →

Randomized Crossover CGM Exercise Timing Trials N = 840 Participants Across 3 Crossover Trials

The 15-Minute After-Dinner Walk That Cuts Blood Sugar Spikes by 22% to 30%—Without Needing Extra Insulin

Bottom-Line Trial Result: Post-Dinner Glucose iAUC: -22% to -30% With a 10–15 Min Walk vs. Sitting (p < 0.001) • Beats a Single 45-Min Morning Walk

Why sitting on the couch right after dinner traps glucose in your bloodstream—and how a relaxed 10-to-15-minute neighborhood stroll opens a mechanical "side door" (contraction-mediated GLUT4 translocation) in your leg muscles right as meal carbohydrates peak.

Condition: Type 2 Diabetes Condition: Prediabetes

7 Min Read • ~1,250 Words Read Study Guide →

DiRECT Cluster-Randomized Trial & ADA Standards of Care N = 298 DiRECT RCT + ADA Guideline Cohort

Just Told You Have Type 2 Diabetes? Take a Breath—Here Is Your Calm, Evidence-Audited First-30-Days Clinical Plan

Bottom-Line Trial Result: Drug-Free T2D Remission (<6.5% HbA1c): 46% Overall (vs. 4% control, ARR: 42%, p < 0.0001) • 86% Remission With >=15 kg Loss

Seeing an HbA1c of 6.5% or higher on your lab portal can feel like a punch to the stomach. You do not have to throw out your pantry tonight or starve yourself tomorrow. Here is a calm, week-by-week First-30-Days plan grounded in American Diabetes Association (ADA) Standards of Care, the Lancet DiRECT remission trial, and stomach-safe Extended-Release Metformin rules.

Condition: Type 2 Diabetes Rx: Metformin ER

8 Min Read • ~1,300 Words Read Study Guide →

NEJM 3-Year Phase 3 RCT (SURMOUNT-1) N = 1,032 Adults (176 Weeks)

NEJM 3-Year SURMOUNT-1 Study: Once-Weekly Tirzepatide Cuts Progression From Prediabetes to Type 2 Diabetes by 94%

Bottom-Line Trial Result: ARR: 11.4% (1.2% vs. 12.6% placebo) • RRR: 94% (HR 0.06, p < 0.001) • NNT = 9 • -22.9% Body Weight

In a landmark 176-week randomized double-blind trial published in the New England Journal of Medicine (N = 1,032 adults with prediabetes and obesity), once-weekly tirzepatide (Mounjaro / Zepbound) reduced progression to Type 2 diabetes by 94% (1.2% vs. 12.6% placebo, HR 0.06, p < 0.001) while sustaining up to 19.7% weight loss. Here are the exact numbers, the 17-week off-treatment rebound data, and what it means for real patients.

Rx: Tirzepatide Condition: Type 2 Diabetes

8 Min Read • ~1,300 Words Read Study Guide →

Clinician Time-Motion & Shared Decision-Making Trials N = 4,820 Clinical Encounters

7 Questions to Bring to Your Next Doctor Visit (So You Never Leave a 15-Minute Appointment Confused)

Bottom-Line Trial Result: Median Time Before Clinician Interruption: 11 Seconds (36% Solicited Agenda) • Written Agenda Cuts Diagnostic Error by 38%

Primary-care time-motion trials show clinicians interrupt a patient’s opening statement after a median of just 11 seconds (PMID: 29972200), and patients immediately forget 40% to 80% of spoken medical instructions (PMID: 12724490). Here are the 7 evidence-backed questions that transform a rushed 15-minute visit into a clear, safe diagnostic and treatment plan.

Doctors Hub (CPT Volume & Bedside) Conditions Hub (Lab Cutoffs)

7 Min Read • ~1,220 Words Read Study Guide →

FDA Food-Effect Bioavailability Crossover Studies N = 3,150 Crossover PK Subjects

What Does "Take With Food" Really Mean on Your Prescription Bottle? (FDA Pharmacokinetics Explained)

Bottom-Line Trial Result: Bile-Salt Drug Absorption (Rivaroxaban 20 mg): 66% Fasting -> ~100% With 500-kcal Meal • Levothyroxine Fasting Gap: +25% TSH Stability

Does "take with food" mean two crackers, a glass of milk, or a full dinner? Under FDA Food-Effect Bioavailability standards and human pharmacokinetic trials, meal timing can shift a drug’s bloodstream absorption (AUC) by -50% to +300% or slash stomach side effects in half (PMID: 12548010, PMID: 9428832). Here is the exact pill-by-pill decoder.

Rx: Metformin ER Rx: Levothyroxine

7 Min Read • ~1,240 Words Read Study Guide →

FDA 12-Year Analysis of 2,070 Human Bioequivalence Trials N = 2,070 Human Crossover Trials

Generic vs. Brand-Name Medications: The 3.5% Bioequivalence Rule & When Pill Fillers Actually Matter

Bottom-Line Trial Result: Mean Generic vs. Brand Difference: 3.56% AUC & 4.35% Cmax (98% Within <10%) • Narrow Therapeutic Index (NTI) Exceptions Decoded

A pervasive myth claims FDA generic drugs are allowed to vary by "up to 20%" from the brand name. In reality, an FDA study of 2,070 human bioequivalence trials (Davit et al., Annals of Pharmacotherapy, PMID: 19776300) proved the average absorption difference between brand and generic is just 3.5%—equivalent to two batches of the brand pill itself. Here is when generics are identical, and the 3 rare exceptions to ask your pharmacist about.

Medications Hub (NADAC Wholesale Prices) Rx: Bupropion XL

7 Min Read • ~1,260 Words Read Study Guide →

Optical PPG vs. 12-Lead Holter ECG Validation Trials N = 1,420 Wearable vs. ECG Recordings

Why Your Smartwatch "Readiness Score" & Heart Rate Variability (HRV) Can Mislead You: Optical PPG vs. Clinical ECG Data

Bottom-Line Trial Result: Nocturnal Resting rMSSD Correlation: r = 0.94–0.98 vs. Gold-Standard ECG • Daytime Motion Artifact Error: 22%–38% Packet Loss

Millions of adults wake up and let a wrist or finger wearable tell them how "recovered" they are based on overnight Heart Rate Variability (rMSSD). Yet clinical validation studies comparing green/infrared optical photoplethysmography (PPG) against gold-standard 12-lead Holter ECG (PMID: 40321810, PMID: 37687769, PMID: 28838896) expose critical blind spots: motion artifacts, premature beats, alcohol, and unvalidated proprietary "Readiness" algorithms.

Condition: Heart & Vascular Hub Supplement: Magnesium Glycinate

8 Min Read • ~1,280 Words Read Study Guide →

NEJM & Lancet Oral GLP-1 Trials N = 831 Adults (36–40 Weeks)

Once-Daily Oral GLP-1 Pill (Orforglipron) Cuts Body Weight by Up to 14.7% Without Fasting Rules: Inside the NEJM & Lancet Trials

Bottom-Line Trial Result: Weight Change: -14.7% vs. -2.3% placebo (Net -12.4%, p < 0.001) • HbA1c -1.8% • Zero Food/Water Fasting Restriction

Unlike weekly GLP-1 injections (Ozempic, Wegovy, Zepbound) or peptide pills that require strict morning fasting (Rybelsus), orforglipron is a small-molecule non-peptide GLP-1 receptor agonist that can be swallowed at any time of day with or without food. Across NEJM and Lancet randomized trials (PMID: 37351564, PMID: 37351565, PMID: 41275875), once-daily orforglipron reduced body weight by up to 14.7% at 36 weeks and lowered HbA1c by -2.10 percentage points.

Rx: Semaglutide Rx: Tirzepatide

8 Min Read • ~1,290 Words Read Study Guide →

NEJM Phase 3 Outcomes Audit • N = 17,604 Randomized Adults

NEJM SELECT Trial (N = 17,604): Once-Weekly Semaglutide Cuts Heart Attacks, Strokes & Cardiovascular Death by 20% in Adults Without Diabetes

Why the FDA granted Wegovy (semaglutide 2.4 mg) its historic cardiovascular risk-reduction label—and what the 20% Relative Risk Reduction vs. 1.5% Absolute Risk Reduction (NNT = 67 over 3.3 years) actually means at your kitchen table.

Atrial Fibrillation & Cardiometabolic Flagship Hub NEJM SURMOUNT-1 Prediabetes Trial (Tirzepatide -94% RRR)

8 Min Read • 1,340 Words Read Study Guide →

3. All Indexed Clinical Studies (120)

Major Medical Journal Watch (NEJM, Lancet, JAMA, BMJ, Nature Med) (120)

Page 1 of 4 • Sorted by Participant Sample Size (N)

Journal Watch & Cohort Study BMJ-703564740

BMJ Recent Research (Clinical Trials): Multi-cancer blood tests to be trialled at GP surgeries in England

More than 20 000 NHS patients at least 200 general practices in England will take part in a trial to examine whether new blood tests can detect multiple cancers in one go.The aim is to provide earlier detection of common cancers including prostate, ovarian, bo

BMJ Recent Research • 2026-11-05 Read Study

Journal Watch & Cohort Study BMJ-4219362849

BMJ Recent Research (Clinical Trials): Ebola UK: British person infected in DRC outbreak will be evacuated home

A British man who has tested positive for Ebola in the Democratic Republic of the Congo (DRC) is to be flown back to the UK.The man, described as a healthcare worker by the Reuters news agency, is reported to be in a stable condition.1This is the first confirm

BMJ Recent Research • 2026-11-05 Read Study

Journal Watch & Cohort Study BMJ-2547830591

BMJ Recent Research (Clinical Trials): Medical news in brief: New psoriasis treatment, endometriosis prescriptions soar, inquiry into hip fracture mortality rates, and other stories

MedicopoliticsTrade union changes name to be more inclusiveThe UK’s Hospital Consultants and Specialists Association (HCSA) formally changed its name to the Hospital Doctors Union (HDU).1 Announcing the change, the HDU president, Claudia Paoloni, a consultant

BMJ Recent Research • 2026-11-05 Read Study

Journal Watch & Cohort Study BMJ-1074584513

BMJ Recent Research (Clinical Trials): We need to build risk management into training curriculums

Holding risk is fundamental for GPs owing to the sheer volume of decisions that we make daily in clinic.1 As a registrar, we have only one learning outcome in our workplace based assessment curriculum that discusses risk, which states that we should focus on “

BMJ Recent Research • 2026-11-05 Read Study

Journal Watch & Cohort Study BMJ-1237167971

BMJ Recent Research (Clinical Trials): Scientist who exposed lead contamination in drinking water wins award for standing up for science

An environmental scientist whose work on lead contamination in Flint, Michigan, drew ire from both officials and campaign groups has been awarded the prestigious Maddox prize for standing up for science.Siddhartha Roy, who is based at Rutgers University, co-le

BMJ Recent Research • 2026-11-05 Read Study

Journal Watch & Cohort Study BMJ-4292036577

BMJ Recent Research (Clinical Trials): Progressive bilateral ptosis and dyspnoea

A man in his 70s presented to the emergency department with progressive bilateral ptosis (fig 1) and increasing dyspnoea over 72 hours. He also reported binocular diplopia after prolonged reading on his phone while waiting to be seen. On questioning, he did no

BMJ Recent Research • 2026-11-05 Read Study

Journal Watch & Cohort Study NATURE_MED-1455905071

Nature Medicine (Longevity & Biotech): Opposing microbiome-mediated axes link modifiable lifestyles to health and chronic diseases

Nature Medicine, Published online: 05 November 2026; doi:10.1038/s41591-026-04744-5 Fecal shotgun metagenomics from 6,803 adults in the Japanese 4D cohort and microbiome-based prediction scores validated across 13 independent and geographically diverse cohorts

Nature Medicine • 2026-11-05 Read Study

Journal Watch & Cohort Study BMJ-2757524118

BMJ Recent Research (Clinical Trials): Airway management for adenotonsillectomy in children

Paediatric adenotonsillectomy, performed for sleep disordered breathing and recurrent or chronic tonsillitis, is among the most common surgical procedures worldwide.1 In a linked randomised clinical trial, Han and colleagues compared the rate of perioperative

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-2891199353

New England Journal of Medicine (Clinical Trials): Durability of Gene Therapy in Patients with Crigler–Najjar Syndrome

New England Journal of Medicine, Volume 395, Issue 18 , Page 1870-1872, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-4096666680

New England Journal of Medicine (Clinical Trials): Angiography-Based Physiological Assessment to Guide Revascularization

New England Journal of Medicine, Volume 395, Issue 18 , Page 1875-1876, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-507743067

BMJ Recent Research (Clinical Trials): Measles: New York reports first death in over 30 years as US outbreak continues to surge

A child has died in a measles outbreak in Lewis County, New York—the first death from the disease in the state in 30 years, the New York State Department of Health said.1The state governor, Kathy Hochul, said that she was “heartbroken” to learn of the child’s

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-3049377867

New England Journal of Medicine (Clinical Trials): Chemogenetic Neuromodulation for Refractory Epilepsy

New England Journal of Medicine, Volume 395, Issue 18 , Page 1867-1869, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-1013339355

BMJ Recent Research (Clinical Trials): Fireworks are an underestimated danger to public health

In 2025, 13 000 people were injured by fireworks.1 Some countries have taken a firm stance: the Netherlands has banned consumer use of fireworks, joining Ireland, Chile, and Australia.2 But in many countries, where consumer bans are not in place (including Ind

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-314067898

BMJ Recent Research (Clinical Trials): Don’t “scapegoat” GPs for rising hospital demand, leaders say

Improved access to general practice is causing pressure on NHS hospitals, the chief executive of NHS England has warned.Speaking to MPs, Jim Mackey said that increased access to GP appointments was leading to a spike in demand and long waits for secondary care

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-3083299949

New England Journal of Medicine (Clinical Trials): From Detection to Action in Computed Tomographic Coronary Angiography

New England Journal of Medicine, Volume 395, Issue 18 , Page 1859-1861, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-44763416

BMJ Recent Research (Clinical Trials): Lenacapavir: Why a newly approved generic version of the blockbuster HIV drug won’t be available in the areas that need it most

A cheap, generic version of one of the world’s best HIV prevention drugs will be out of reach for patients in at least 26 countries, the US manufacturer of the original drug has confirmed.The first generic version of lenacapavir—the only twice-a-year injectabl

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study NATURE_MED-3471426628

Nature Medicine (Longevity & Biotech): A tumor transcriptomic atlas across eight decades of life reveals distinct features of early-onset colorectal cancer

Nature Medicine, Published online: 04 November 2026; doi:10.1038/s41591-026-04771-2 The incidence of early-onset colorectal cancer is rising, but whether it is biologically distinct from average-onset disease is unclear. Mapping of the transcriptome of colorec

Nature Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-4195503725

BMJ Recent Research (Clinical Trials): Prioritising fun: the GP finding community on the golf course

For GP James Thambyrajah, playing golf is a calming activity that slows everything down.“I’m focused on the ball, plotting my way around the course. There’s nothing quite like hitting a great shot,” he says.Thambyrajah finds a lot of joy and peace on the cours

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-151668272

BMJ Recent Research (Clinical Trials): Interventions for adhesive capsulitis: systematic review and network meta-analysis of randomised controlled trials

AbstractObjectiveTo compare the benefits and harms of therapeutic interventions for adhesive capsulitis.DesignSystematic review and network meta-analysis of randomised controlled trials.Data sourcesMedline, Cochrane Library, Embase, Web of Science, and Scopus

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-154625833

BMJ Recent Research (Clinical Trials): Gestures that acknowledge I’m here

At the age of 16 I was admitted to hospital with a catastrophic gastrointestinal bleed from a duodenal ulcer. During the hours after admission, my blood pressure fell to 55/30 mm Hg and I received 11 units of blood and two of plasma. A priest was summoned to a

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-180158625

BMJ Recent Research (Clinical Trials): Do abortion drugs pollute the water supply?

On 9 September the US Environmental Protection Agency (EPA) announced that it will begin testing water supplies for mifepristone and misoprostol,1 the drugs used for medical abortion, among more than 1400 pharmaceuticals, pesticides, and other chemicals.2The t

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-2152486546

BMJ Recent Research (Clinical Trials): Perioperative respiratory adverse events in children undergoing adenotonsillectomy with laryngeal mask airway versus endotracheal tube ventilation: multicentre, randomised controlled trial

AbstractObjectiveTo assess the effect of ventilation with a laryngeal mask airway (LMA) compared with endotracheal tube (ETT) on perioperative respiratory adverse events (PRAEs) in children undergoing adenotonsillectomy.DesignMulticentre, randomised, parallel

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-3719667783

BMJ Recent Research (Clinical Trials): AI enabled biological threats require international governance, not voluntary safeguards

Anthropic’s disclosure of scientists using, or attempting to use, the AI tool Claude for biological research that could support the development of bioweapons deserves neither dismissal nor exaggeration.1 The five reported cases do not establish malicious inten

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-1831904742

BMJ Recent Research (Clinical Trials): Boost health worker placements in rural areas, Chris Whitty says

Health challenges in England’s rural areas are not being recognised or supported, the nation’s top doctor says.In his annual report on the state of the public’s health,1 chief medical officer Chris Whitty highlighted the “unique challenges” faced by people liv

BMJ Recent Research • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-2873167172

New England Journal of Medicine (Clinical Trials): PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer

New England Journal of Medicine, Volume 395, Issue 18 , Page 1872-1875, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-2354027207

New England Journal of Medicine (Clinical Trials): Atherosclerosis across the Adult Lifespan — A Call to Act from REACT

New England Journal of Medicine, Volume 395, Issue 18 , Page 1861-1863, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-2774410820

New England Journal of Medicine (Clinical Trials): Intravenous Thrombolysis for Acute Ischemic Stroke — New Directions

New England Journal of Medicine, Volume 395, Issue 18 , Page 1841-1847, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study NATURE_MED-3140292372

Nature Medicine (Longevity & Biotech): Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial

Nature Medicine, Published online: 04 November 2026; doi:10.1038/s41591-026-04745-4 In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to encoura

Nature Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study NEJM-1164859457

New England Journal of Medicine (Clinical Trials): Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis

New England Journal of Medicine, Volume 395, Issue 18 , Page 1805-1817, November 5, 2026.

New England Journal of Medicine • 2026-11-04 Read Study

Journal Watch & Cohort Study BMJ-2911245072

BMJ Recent Research (Clinical Trials): David Oliver: Unanswered questions over Burnham’s pledge on social care

In September the prime minister, Andy Burnham, pledged to build a “national care service” in England, with free access to social care services and where “everyone contributes and everyone is covered.”1 He added that Louise Casey—already tasked by the governmen

BMJ Recent Research • 2026-11-04 Read Study

4. Quick Guide • Never Get Fooled by a Headline Again

How to Read a Clinical Study in 30 Seconds

Read FDA Bioequivalence Guide →

1. Relative Risk (RRR) vs. Absolute Risk (ARR)

If a drug drops heart attack risk from 2.0% to 1.0%, headlines scream “50% Relative Risk Reduction!” The real Absolute Risk Reduction (ARR) is 1.0%—meaning 100 people must take the drug (NNT = 100) to prevent 1 event.

2. Double-Blind RCT vs. Observational Association

Food questionnaires and observational cohorts can only show correlation (often confounded by wealth or exercise). Only a Randomized Controlled Trial (RCT) can prove that a drug or supplement actually caused the outcome.

3. Statistical p-Value vs. Clinical Meaning

In a massive 10,000-person trial, a blood pressure drop of 0.8 mmHg can achieve p < 0.05 (statistically significant) while having zero meaningful benefit in your daily life. Always look at the actual effect size.

4. Surrogate Lab Markers vs. Hard Outcomes

Raising HDL cholesterol or tweaking a single lab biomarker does not automatically prevent strokes or extend lifespan. Prioritize trials that measure hard patient outcomes (survival, remission, sleep latency, or GI tolerability).

Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.